cs1001
mAbexperimental
Clinical trial activity
22 trials · 15 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
15
Phase 3
8
Phase 4
0
Earliest trial started Oct 19, 2017 (NCT03312842)
Timeline
Indications
Studied for
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Esophageal Neoplasms · Phase 3
- Hair Color · Phase 3
- Hodgkin Disease · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma, Extranodal NK-T-Cell · Phase 3
- Lymphoma, T-Cell · Phase 2
- Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 2/Phase 3
- Stomach Neoplasms · Phase 3
Mechanism of action
- Programmed cell death 1 ligand 1BINDING AGENT
Programmed cell death 1 ligand 1 binding agent
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594535 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06987734 | Phase 2 | Jun 19, 2025 | Huazhong University of Science and Technology, Pfizer |
| NCT06745336 | Phase 3 | Jun 15, 2025 | Applied Biology, Inc. |
| NCT06617416 | Phase 3 | Sep 30, 2024 | Akeso Pharmaceuticals, Inc., Shandong University |
| NCT05700448 | Phase 3 | Jul 31, 2024 | CStone Pharmaceuticals |
| NCT06217757 | Phase 1/Phase 2 (Phase 2) | Apr 18, 2024 | Sichuan University |
| NCT07247227 | N/A | Oct 10, 2023 | — |
| NCT06097962 | Early Phase 1 (Phase 1) | Jul 1, 2023 | Base Therapeutics (Shanghai) Co., Ltd., People's Liberation Army of China |
| NCT05940532 | Phase 2 | Jun 14, 2023 | Central South University |
| NCT05623267 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2023 | Sun Yat-Sen University |
| NCT04472858 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2021 | CStone Pharmaceuticals, Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| NCT04421352 | Phase 1 | Jun 30, 2020 | CStone Pharmaceuticals, Sichuan University |
| NCT04200404 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2019 | Bayer, CStone Pharmaceuticals |
| NCT04194801 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2019 | CStone Pharmaceuticals |
| NCT04187352 | Phase 3 | Dec 30, 2019 | CStone Pharmaceuticals |
| NCT03802591 | Phase 3 | Mar 28, 2019 | CStone Pharmaceuticals |
| NCT03789604 | Phase 3 | Dec 13, 2018 | CStone Pharmaceuticals |
| NCT03744403 | Phase 1 | Dec 4, 2018 | CStone Pharmaceuticals |
| NCT03728556 | Phase 3 | Oct 26, 2018 | CStone Pharmaceuticals, Shantou University |
| NCT03595657 | Phase 2 | Jun 12, 2018 | CStone Pharmaceuticals |
| NCT03505996 | Phase 2 | Jun 1, 2018 | CStone Pharmaceuticals |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CStone Pharmaceuticals | For profit | 13 | 12 | 3 | 2017 |
| Sichuan University | Academic/Hospital | 2 | 1 | 2 | 2020 |
| Akeso Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2024 |
| Applied Biology, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Base Therapeutics (Shanghai) Co., Ltd. | For profit | 1 | 1 | 1 | 2023 |
| Bayer | For profit | 1 | 0 | 1 | 2019 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| EQRx, Inc. | For profit | 1 | 1 | 1 | — |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
| People's Liberation Army of China | Government | 1 | 0 | 1 | 2023 |
| Pfizer | For profit | 1 | 0 | 1 | 2025 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Shantou University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Suzhou Zelgen Biopharmaceuticals Co.,Ltd | For profit | 1 | 1 | 1 | 2021 |
15 organizations
Page 1 / 1